Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Dec 8;11(12):e007487. doi: 10.1136/jitc-2023-007487

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Schematic illustration of the mechanism by which ALDH2 drives immune evasion. ALDH2-mediated aldehyde metabolism drives tumor immune evasion by modulating the expression of VISTA immune checkpoint in tumors. Blocking ALDH2 downregulates VISTA expression by suppressing the activation of NOD/NF-κB signaling pathway, resulting in improving cytotoxic activity of CD8⁺ T cell and reshaping the global immune landscape, thereby curbing tumor growth. Notably, inhibiting ALDH2 enhances the antitumor immune response of ICB therapy. KO, knock out.